Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 676 - 700 of 11090 in total
Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in...
Approved
Investigational
Technetium Tc-99m tetrofosmin is a drug used in nuclear myocardial perfusion imaging. The radioisotope, technetium-99m, is chelated by two 1,2-bis[di-(2-ethoxyethyl)phosphino]ethane ligands which belong to the group of diphosphines and which are referred to as tetrofosmin. It is a lipophilic technetium phosphine dioxo cation that was formulated into a freeze-dried kit...
Approved
Matched Description: … [A31592] Technetium Tc-99m tetrofosmin was developed by GE Healthcare and FDA approved on February 9, ... lipophilic technetium phosphine dioxo cation that was formulated into a freeze-dried kit which yields an
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a...
Approved
Investigational
Matched Iupac: … (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
Matched Description: … It is approved for use in Japan and is currently in trials in the U.S. ... Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic …
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011....
Approved
Matched Description: … [A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. ... The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. …
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Iupac: … carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6-yl]formamido}-3-(3-methanesulfonylphenyl)propanoic acid
Matched Description: … The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. ... Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome) …
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is...
Approved
Investigational
Matched Categories: … Nucleic Acid Synthesis Inhibitors …
Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Description: … [DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. …
Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart...
Approved
Matched Description: … long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an ... [A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR …
Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193] Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Description: … Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside ... granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an ... In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated …
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to...
Approved
Investigational
Matched Description: … Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, ... [A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the …
Alfacalcidol, or 1-alpha-hydroxycholecalciferol or 1-alpha-hydroxyvitamin D3, is a non-endogenous analogue of vitamin D. It plays an essential function in calcium homeostasis and bone metabolism. Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones. The pharmacological...
Approved
Nutraceutical
Matched Description: … [A234044] It plays an essential function in calcium homeostasis and bone metabolism. …
Matched Categories: … alendronic acid and alfacalcidol, sequential …
Phenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms such as burning and pain during urination. In the USA, this drug was previously marked by Roche but has been discontinued by the FDA. It is...
Approved
Matched Description: … red color, as it is considered an azo dye. ... Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or …
A vitamin D that can be regarded as a reduction product of vitamin D2.
Approved
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is...
Approved
Investigational
Matched Description: … [L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor. ... On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA …
Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Approved
Approved
Investigational
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an ... L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved
Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the...
Approved
Nutraceutical
Matched Description: … Ergocalciferol is an inactivated vitamin D analog. ... by US Pharm Holdings and was FDA approved in 1941. ... [A177637] The first approved product containing ergocalciferol under the FDA records was developed …
Barium sulfate is an inorganic compound with the chemical formula BaSO4 . Barium sulfate occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield . This drug is used as a contrast agent in...
Approved
Matched Description: … Barium sulfate is an inorganic compound with the chemical formula BaSO4 [L1957]. …
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids...
Approved
Matched Description: … It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine …
Sodium stibogluconate is a medicine used to treat leishmaniasis and is only available for administration by injection. It belongs to the class of medicines known as the pentavalent antimonials. Sodium stibogluconate is sold in the UK as Pentostam (manufactured by GlaxoSmithKline). Widespread resistance has limited the utility of sodium stibogluconate,...
Approved
Investigational
Matched Description: … It is also being investigated as an anti-tumor agent. …
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an ... In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated …
Novobiocin is an antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964...
Approved
Investigational
Vet approved
Withdrawn
Matched Description: … Novobiocin is an antibiotic compound derived from _Streptomyces niveus_. ... Extra Pharmacopoeia, 30th ed, p189) Novobiocin sodium, a salt form of novobiocin, was initially approved
Matched Categories: … Nucleic Acid Synthesis Inhibitors …
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated...
Approved
Matched Description: … [A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 ... [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated …
Displaying drugs 676 - 700 of 11090 in total